Prosecution Insights
Prosecution Insights
11 pending office actions • 7 art units • 10 examiners • 0 of 11 (0%) have an AI response strategy ready • 16 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 7 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 7 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (9%) |
| §101 + other | 1 (9%) |
| §103 only | 2 (18%) |
| §102 only | 1 (9%) |
| §112 only | 3 (27%) |
| Multi-statute (no §101) | 3 (27%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| REYNOLDS, FRED H | 2 | 33.1% | +39.0% |
| DURYEE, ALEXANDER MARSH | 1 | 32.6% | +40.6% |
| SINGH, ANOOP KUMAR | 1 | 42.8% | +67.4% |
| FETTEROLF, BRANDON J | 1 | 51.4% | +17.1% |
| HOFFMAN, SUSAN COE | 1 | 54.2% | +25.6% |
| KONOPKA, CATHERINE ANNE | 1 | 58.2% | +64.5% |
| LOUNTOS, GEORGE THEMISTOCLIS | 1 | 33.3% | +0.0% |
| THUESON, HANNA MARIE | 1 | 77.3% | +26.5% |
| ZHU, JIANJIAN | 1 | 61.0% | +83.7% |
| MIANO, JOSEPH PAUL | 1 | 36.1% | +64.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17686669 | EXPANDABLE LIVER ORGANOIDS, MEDIA COMPOSITION FOR DIFFERENTIATION THEREOF, AND METHOD FOR PRODUCING LIVER ORGANOIDS USING THE SAME | THUESON, HANNA MARIE | 46d overdue |
| 17231278 | HUMAN INTESTINAL EPITHELIUM MODEL AND METHOD FOR PREPARING SAME | MIANO, JOSEPH PAUL | 16d overdue |
| 18283589 | COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING DUAL EXPRESSIONVECTOR FOR SIMULTANEOUSLY EXPRESSING PROTEIN PRESENT IN CELL AND PROTEIN SECRETED OUT OF CELL | KONOPKA, CATHERINE ANNE | 7d |
| 18312110 | NOVEL PEPTIDE HAVING ANTI-INFLAMMATORY AND TISSUE REGENERATIVE ACTIONS | REYNOLDS, FRED H | 61d |
| 18282160 | NOVEL BICYCLIC COMPOUND, OPTICAL ISOMER THEREOF OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, USE THEREOF, AND PREPARATION METHOD THEREFOR | REYNOLDS, FRED H | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17686669 | EXPANDABLE LIVER ORGANOIDS, MEDIA COMPOSITION FOR DIFFERENTIATION THEREOF, AND METHOD FOR PRODUCING LIVER ORGANOIDS USING THE SAME | THUESON, HANNA MARIE | 46d overdue |
| 17231278 | HUMAN INTESTINAL EPITHELIUM MODEL AND METHOD FOR PREPARING SAME | MIANO, JOSEPH PAUL | 16d overdue |
| 18283589 | COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING DUAL EXPRESSIONVECTOR FOR SIMULTANEOUSLY EXPRESSING PROTEIN PRESENT IN CELL AND PROTEIN SECRETED OUT OF CELL | KONOPKA, CATHERINE ANNE | 7d |
| 17598916 | METHOD FOR PRODUCING CAR GENE-INTRODUCED NK CELLS AND USE THEREOF | ZHU, JIANJIAN | 9d |
| 18572480 | PHARMACEUTICAL COMPOSITION COMPRISING LIPASE INHIBITOR FOR TREATMENT OR TREATMENT OF RNA VIRAL INFECTIONS | FETTEROLF, BRANDON J | 16d |
| 18312110 | NOVEL PEPTIDE HAVING ANTI-INFLAMMATORY AND TISSUE REGENERATIVE ACTIONS | REYNOLDS, FRED H | 61d |
| 18889046 | METHOD FOR PREVENTING OR TREATING MUSCLE DISEASE | DURYEE, ALEXANDER MARSH | — |
| 18837056 | TWO-DIMENSIONAL CULTURE METHOD HAVING CLEAR CHEMICAL COMPOSITION FOR CULTURING THREE-DIMENSIONAL INTESTINAL ORGANOID-DERIVED INTESTINAL STEM CELL AGGREGATE | SINGH, ANOOP KUMAR | — |
| Art Unit | Apps |
|---|---|
| 1658 | 2 |
| 1631 | 2 |
| 1626 | 1 |
| 1655 | 1 |
| 1635 | 1 |
| 1652 | 1 |
| 1638 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18889046 | METHOD FOR PREVENTING OR TREATING MUSCLE DISEASE | DURYEE, ALEXANDER MARSH | — | §112 | Non-Final OA | — | Pending | Sep 18, 2024 |
| 18837056 | TWO-DIMENSIONAL CULTURE METHOD HAVING CLEAR CHEMICAL COMPOSITION FOR CULTURING THREE-DIMENSIONAL INTESTINAL ORGANOID-DERIVED INTESTINAL STEM CELL AGGREGATE | SINGH, ANOOP KUMAR | — | §112 | Non-Final OA | — | Pending | Aug 08, 2024 |
| 18572480 | PHARMACEUTICAL COMPOSITION COMPRISING LIPASE INHIBITOR FOR TREATMENT OR TREATMENT OF RNA VIRAL INFECTIONS | FETTEROLF, BRANDON J | 1626 | §103 | Final Rejection | 16d | Pending | Dec 20, 2023 |
| 18290222 | COMPOSITION CONTAINING ACANTHOPANAX EXTRACT AND GARCINIA CAMBOGIA EXTRACT OR COMPOUND ISOLATED THEREFROM AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF LIVER DISEASE | HOFFMAN, SUSAN COE | 1655 | §103 | Final Rejection | — | Pending | Nov 10, 2023 |
| 18283589 | COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING DUAL EXPRESSIONVECTOR FOR SIMULTANEOUSLY EXPRESSING PROTEIN PRESENT IN CELL AND PROTEIN SECRETED OUT OF CELL | KONOPKA, CATHERINE ANNE | 1635 | §103§112Other | Non-Final OA | 7d | Pending | Sep 22, 2023 |
| 18282160 | NOVEL BICYCLIC COMPOUND, OPTICAL ISOMER THEREOF OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, USE THEREOF, AND PREPARATION METHOD THEREFOR | REYNOLDS, FRED H | 1658 | §101 | Non-Final OA | — | Pending | Sep 14, 2023 |
| 18312110 | NOVEL PEPTIDE HAVING ANTI-INFLAMMATORY AND TISSUE REGENERATIVE ACTIONS | REYNOLDS, FRED H | 1658 | §101§102§103§112DPOther | Final Rejection | 61d | Pending | May 04, 2023 |
| 17767425 | MONO-HYDROXY OR DI-HYDROXY DERIVATIVES OF POLYUNSATURATED FATTY ACIDS, PRODUCTION METHOD THEREFOR, AND USE THEREOF | LOUNTOS, GEORGE THEMISTOCLIS | 1652 | §102Other | Final Rejection | 45d overdue | Pending | Apr 07, 2022 |
| 17686669 | EXPANDABLE LIVER ORGANOIDS, MEDIA COMPOSITION FOR DIFFERENTIATION THEREOF, AND METHOD FOR PRODUCING LIVER ORGANOIDS USING THE SAME | THUESON, HANNA MARIE | 1638 | §102§103§112 | Final Rejection | 46d overdue | Pending | Mar 04, 2022 |
| 17598916 | METHOD FOR PRODUCING CAR GENE-INTRODUCED NK CELLS AND USE THEREOF | ZHU, JIANJIAN | 1631 | §112Other | Non-Final OA | 9d | Pending | Sep 28, 2021 |
| 17231278 | HUMAN INTESTINAL EPITHELIUM MODEL AND METHOD FOR PREPARING SAME | MIANO, JOSEPH PAUL | 1631 | §103§112 | Non-Final OA | 16d overdue | Pending | Apr 15, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial